Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | RAPGEF4 | Q8WZA2 | 7/20 | 0.50 |
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYTH2 | Q99418 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047218 | 0.78 | RAPGEF4 (0.67) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL21117641 | 0.78 | CA1 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL3241201 | 0.77 | RAPGEF4 (0.46) | RAPGEF4TSHRALDH1A1HTTLMNA | |
| SCHEMBL8271353 | 0.76 | CA1 (0.54) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL330754 | 0.76 | CA1 (0.54) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL16140106 | 0.74 | CA1 (0.52) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL113366 | 0.74 | CA1 (0.52) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL10846507 | 0.74 | CA1 (0.58) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL23788 | 0.74 | CA1 (0.58) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL7555257 | 0.74 | CYP1A2 (0.39) | CA1CA2POLBTSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | claimed |
| EP-1417190-B1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-10-22 | — | — | EP | claimed |
| EP-1416933-B8 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | claimed |
| US-20070265248-A1 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2007-11-15 | — | — | US | claimed |
| US-7115607-B2 | Substituted piperazinyl amides and methods of use | AMGEN INC. (US) | 2006-10-03 | — | — | US | claimed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | claimed |
| EP-1416933-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgem, Inc. (US) | 2004-05-12 | — | — | EP | claimed |
| EP-1417190-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgen Inc. (US) | 2004-05-12 | — | — | EP | claimed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | claimed |
| US-20030220324-A1 | Substituted piperazines and methods of use | AMGEN INC. | 2003-11-27 | — | — | US | claimed |
| WO-2003009847-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM, INC. (US) | 2003-02-06 | — | — | WO | claimed |
| WO-2003009850-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC. (US) | 2003-02-06 | — | — | WO | claimed |
| US-20020065271-A1 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | PEYMAN ANUSCHIRWAN (DE) | 2002-05-30 | — | — | US | claimed |
| US-6313119-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-11-06 | — | — | US | claimed |
| EP-1049677-A1 | NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2000-11-08 | — | — | EP | claimed |
| WO-1999037621-A1 | NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-29 | — | — | WO | claimed |
| US-7560460-B2 | Substituted piperazines and methods of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| EP-0219923-A1 | Antibiotic derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-04-29 | — | — | EP | disclosed |
| EP-0191989-A1 | Antibiotic isoxazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220324-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | CA1 4542/4885CA2 3148/4885MMP1 2051/4885 |
| US-20070265248-A1 | Substituted piperazines and methods of use | MC5R, MC4R, MC1R | CA1 4542/4885CA2 3148/4885MMP1 2051/4885 |
| US-20020065271-A1 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | SOST, SELPLG, BST2 | CA1 957/4885CA2 667/4885MMP1 332/4885 |
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | CA1 4656/4885CA2 3303/4885MMP1 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.